API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
https://www.prnewswire.com/news-releases/biosight-launches-a-phase-12-clinical-trial-of-aspacytarabine-in-combination-with-venetoclax-for-first-line-aml-induction-therapy-followed-by-aspacytarabine-consolidation-301685067.html
https://www.prnewswire.com/news-releases/biosight-granted-orphan-drug-designation-from-the-fda-for-aspacytarabine-for-the-treatment-of-myelodysplastic-syndromes-301596832.html
https://www.globenewswire.com/news-release/2022/01/06/2362832/0/en/Biosight-Reports-Final-Primary-Endpoint-Data-from-Phase-2b-Study-of-Aspacytarabine-BST-236-for-First-Line-Acute-Myeloid-Leukemia-Therapy.html
https://www.globenewswire.com/news-release/2021/11/12/2333405/0/en/Biosight-Announces-Initiation-of-Phase-2-Clinical-Trial-of-Aspacytarabine-for-MDS-and-AML.html
https://www.globenewswire.com/news-release/2021/08/16/2281034/0/en/Biosight-Announces-Initiation-of-Investigator-Sponsored-Phase-2-Clinical-Trial-of-Aspacytarabine-for-Relapsed-Refractory-AML-and-MDS-with-the-Groupe-Francophone-des-My%C3%A9lodysplasies.html
https://www.globenewswire.com/news-release/2021/07/06/2258015/0/en/Advaxis-and-Biosight-Announce-Entry-into-Definitive-Merger-Agreement.html
https://www.globenewswire.com/news-release/2020/11/05/2121264/0/en/Biosight-to-Present-Updated-Clinical-Data-from-Ongoing-Phase-2b-Study-of-Aspacytarabine-BST-236-at-the-2020-ASH-Annual-Meeting.html